Table 1 Univariate analysis comparing survivors and non-survivors at 30 days from infection onset

Male sex, (%)

78.7

69.7

1.60 (0.64–4.05)

Age, median (range)

62 (15–89)

55 (18–89)

–

Comorbidities, (%)

 Pneumonia

58.7

60.6

0.92 (0.40–2.13)

 Diabetes

17.3

6.1

3.25 (0.69–15.31)

 Liver cirrhosis

4.0

6.1

0.65 (0.10–4.06)

  Malignant tumor

12.0

12.1

0.99 (0.28–3.47)

 Trauma

16.0

24.2

0.60 (0.22–1.63)

ICU stay, (%)

86.7

42.4

8.82 (3.38–23.02)

Inpatient days, median (range)

25 (6–155)

35 (12–163)

–

Deep vein intubation, (%)

89.3

78.8

2.25 (0.74–6.85)

Mechanical ventilation, (%)

81.3

60.0

2.49 (1.00–6.22)

Polymicrobial infection, (%)

 Fungi

12.0

15.6

0.76 (0.24–2.48)

 Other bacteria

46.7

51.5

0.82 (0.36–1.87)

A.baumannii isolated from other sites during hospital stay, (%)

 Sputum

80.0

78.8

1.08 (0.39–2.95)

 Cerebrospinal fluid

4.0

3.0

1.33 (0.13–13.31)

Usage of antibiotic, mean (range), (%)

 Number of antibiotic classes used

3.16 (1–6)

3.52 (1–5)

–

 Empirical antimicrobial therapy before isolating from blood

100

100

–

 Change antimicrobial within 48 h after isolating from blood

53.3

87.9

0.16 (0.05–0.49)

 Combination therapy

36.0

54.5

0.41 (0.18–0.96)

Laboratory examination, mean ± SD, (%)

 White blood cell count (× 10⁹/L)

13.2 ± 9.70

16.0 ± 11.0

–

 Leukopenia (< 4 × 10⁹/L)

18.7

6.1

3.56 (0.76–16.65)

 Hemoglobin (g/L)

90.5 ± 21.4

94.7 ± 19.3

–

 Anemia (< 100 g/L)

69.3

60.6

1.47 (0.63–3.45)

 Platelet count (× 10⁹/L)

123.1 ± 106.7

201.7 ± 104.0

–

 Thrombocytopenia (< 50 × 10⁹/L)

36.0

6.1

8.72 (1.93–39.30)